Cargando…
The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development
BACKGROUND: Standard biopsy for prostate cancer diagnosis is an unpleasant and sometimes painful procedure with a detection rate as low as around 50%. Consequently, an accurate blood-based test would be highly desirable to improve the predictive accuracy. However, the clinical value of a new blood t...
Autores principales: | Fridhammar, Adam, Axelsson, Ulrika, Persson, Ulf, Bjartell, Anders, Borrebaeck, Carl A. K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895873/ https://www.ncbi.nlm.nih.gov/pubmed/32780268 http://dx.doi.org/10.1007/s41669-020-00226-7 |
Ejemplares similares
-
MRI-only radiotherapy from an economic perspective: Can new techniques in prostate cancer treatment be cost saving?
por: Persson, Emilia, et al.
Publicado: (2022) -
Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
por: Eliasson, Björn, et al.
Publicado: (2022) -
The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
por: Hellsten, Rebecka, et al.
Publicado: (2022) -
A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: study protocol of the SCAN-B resilience study
por: Axelsson, Ulrika, et al.
Publicado: (2018) -
Psychometric properties of the Connor-Davidson Resilience Scale (CD-RISC) in a non-clinical population in Sweden
por: Velickovic, Katarina, et al.
Publicado: (2020)